DRUG RESPONSE PREDICTION FOR DRY EYE DISEASE USING PYTHON AND TENSORFLOW

CO8811 - PROJECT REPORT

Submitted by

HARSHITHAA M	**211420118023**
PAVITHRA S	**211420118035**
SAI MONIKA S	**211420118041**

in partial fulfillment for the award of the degree

of

BACHELOR OF ENGINEERING

in

COMPUTER AND COMMUNICATION ENGINEERING

PANIMALAR ENGINEERING COLLEGE

(An Autonomous Institution, Affiliated to Anna University, Chennai)

MARCH 2024

BONAFIDE CERTIFICATE

Certified that this project report **"DRUG RESPONSE PREDICTION FOR DRY EYE DISEASE USING PYTHON AND TENSORFLOW"** is the Bonafide work of **HARSHITHAA M (211420118023), PAVITHRA S (211420118035), SAI MONIKA S (211420118041)** who carried out the project work under my supervision.

SIGNATURE

Dr.B.ANNI PRINCY M.E., Ph.D.,

HEAD OF THE DEPARTMENT

PROFESSOR,
COMPUTER AND COMMUNICATION ENGINEERING,
PANIMALAR ENGINEERING COLLEGE,
NAZARATHPETTAI
POONAMALLEE, CHENNAI- 600123.

SIGNATURE

Dr.B.ANNI PRINCY M.E., Ph.D.,

SUPERVISOR

PROFESSOR,
COMPUTER AND COMMUNICATION ENGINEERING,
PANIMALAR ENGINEERING COLLEGE
NAZARATHPETTAI
POONAMALLEE, CHENNAI- 600123.

Certified that the above candidate(s) was/ were examined in the End Semester Project Viva-Voce Examination held on 26.03.2024

INTERNAL EXAMINER **EXTERNAL EXAMINER**

ACKNOWLEDGEMENT

We express our deep gratitude to our respected Secretary and Correspondent **Dr.P.CHINNADURAI, M.A., Ph.D.** for his kind words and enthusiastic motivation, which inspired us a lot in completing this project

We would like to extend our heartfelt and sincere thanks to our Directors Tmt. **C.VIJAYARAJESWARI, Dr. C. SAKTHIKUMAR, M.E., Ph.D**., and **Dr.SARANYASREE SAKTHIKUMAR B.E., M.B.A., Ph.D**., for providing us with the necessary facilities for completion of this project.

We also express our gratitude to our Principal **Dr.K.MANI, M.E., Ph.D.,** for his timely concern and encouragement provided to us throughout the course.

We thank our HOD of Computer and Communication Engineering Department, **Dr. B. ANNI PRINCY, M.E., Ph.D**., Professor, for the support extended throughout the project.

We would like to thank our supervisor, **Dr. B. ANNI PRINCY, M.E., Ph.D**., Professor, and all the faculty members of the Department of Computer and Communication Engineering for their advice and suggestions for the successful completion of the project.

HARSHITHAA M

PAVITHRA S

SAI MONIKA S

TABLE OF CONTENTS

ABSTRACT

Dry Eye Disease (DED) is a prevalent ocular condition that can vary in severity and responsiveness to different treatment modalities. Personalized medicine approaches, including the prediction of individual patient responses to specific drugs, are essential for optimizing therapeutic outcomes. Our project proposes a novel framework for drug response prediction in Dry Eye Disease, leveraging Python programming language and the TensorFlow machine learning library. The research utilizes a comprehensive dataset encompassing the binding values of Antioxidants and the interaction score between them that are relevant to dry eye conditions. Data preprocessing techniques are applied to ensure the quality and relevance of the dataset for predictive modeling. This research explores various machine learning algorithms available in TensorFlow, such as Logistic Regression, Random Forest, Deep Neural Network, focusing on their ability to predict individual drug responses for dry eye patients. The workflow involves feature engineering, model training, and fine-tuning to optimize the predictive performance of the selected model. TensorFlows capabilities in implementing deep learning architectures are harnessed to capture intricate patterns in the data that may contribute to drug response variations. The research employs cross-validation techniques to assess the models generalizability and robustness. The developed predictive model holds the potential to guide clinicians in selecting the most effective treatment strategies tailored to individual patient profiles, thereby enhancing the overall management of Dry Eye Disease. The integration of Python and TensorFlow showcases the versatility and efficiency of these tools in the realm of personalized medicine, providing a valuable framework for predicting drug responses in the context of ocular disorders. This research contributes to advancing the field of individualized treatment approaches in ophthalmology.

LIST OF FIGURES

LIST OF ABBREVIATIONS

DED	Dry Eye Disease
NIH	National Institutes of Health
DNN	Deep Neural Network
CNN	Convolutional Neural Network
RNN	Recurrent Neural Network
ANN	Artificial Neural Network
ROC	Receiver Operating Characteristic
AUC	Area Under Curve

CHAPTER 1

INTRODUCTION

Dry eye disease (Conjunctivitis) is a multifactorial disease that occurs due to climate change, excessive usage of cellular digital devices that results in symptoms like redness, discomfort, pain during blinking and irritation. Synthetic drugs like cyclosporine and varenicline are used for treatment .But due to its side effects like nausea, vomiting, sedation, hypotension, bradycardia, drowsiness, hyperhidrosis, agitation and fear/anxiety there is a need of new and natural alternative for treatment .Antioxidants are the potential alternatives for the treatment. However, the process of finding new drugs takes a long time and is laborious. In this way, the utilization of python and tensorflow is an answer to reduce time consumption and to accurately predict the drug response. The aim of this work is to predict dry eye disease using the TensorFlow machine learning framework which typically involves developing a predictive model. It utilizes a comprehensive dataset encompassing the binding values of Antioxidants, PH, Hardness, Solids, Chloramines, Sulfate, Conductivity, Organic_carbon, Trihalomethane, Turbidity, Potability.

The objective of such a prediction model can be multifaceted and may include:

- Early Detection
- Personalized Medicine
- Improving Diagnosis Accuracy
- Reduced Side Effects

Early Detection: Prediction models can aid in identifying diseases or health conditions at an early stage, allowing for timely intervention and treatment. Early detection can significantly improve patient outcomes by enabling proactive management of diseases when they are more treatable or manageable.

Personalized Medicine: Prediction models can be utilized to tailor medical treatments and interventions to individual patients based on their unique characteristics, such as genetic makeup, lifestyle factors, and medical history. By considering individual variability, personalized medicine aims to optimize treatment efficacy while minimizing adverse effects.

Improving Diagnosis Accuracy: Prediction models can enhance the accuracy and reliability of medical diagnoses by integrating various data sources, including clinical observations, imaging studies, laboratory tests, and patient demographics. By analyzing these data comprehensively, prediction models can assist healthcare providers in making more accurate and confident diagnoses.

Reduced Side Effects: Prediction models can help identify patients who are higher risk of experiencing adverse drug reactions or treatment-related side effects. By predicting individual susceptibility to side effects, healthcare providers can adjust treatment regimens accordingly, such as modifying drug dosages or selecting alternative therapies, to minimize the occurrence of adverse events

As medicine advances, novel classes of medicines emerge unceasingly with the hope to effectively reverse the disease process or prevent further detrimental outcomes. Over the last decades, therapeutic agents have become more targeted toward a specific part or parts of the patho physiology. Examples included immune checkpoint inhibitors in cancer immunotherapy, epidermal or fibroblast growth factor receptor inhibitors, and novel chemotherapeutic agents such as S-1, and an ever-expanding array of monoclonal antibodies targeting both neoplastic or inflammatory.

While medication is a known risk factor for ocular surface diseases, the Dry eye report on iatrogenic dry eye focused on conventional medications such as antihypertensive, antidepressants, antihistamines, corticosteroids, or non steroidal anti-inflammatory drugs.

Like any other treatment-emergent adverse outcomes, incidences of ophthalmic side effects such as dry eyes following the use of a novel medication take time to be reported, usually in an isolated case report or small series. Thus, it is imperative that we review this topic periodically to keep ourselves updated regarding the possible linkage between a drug and ophthalmic manifestations.

Recently, it was found that dry eye is an inflammatory disease that shares many features with autoimmune diseases. The pathogenesis of dry eye may be due to stress on the ocular surface (infection, environmental factors, endogenous stress, genetic factors, and antigens) DES is a chronic disease, particularly among older people, but proper treatment decreases symptoms and, eventually, ocular damage .

The prevalence rate is 5–50%, which may be up to 75% in adults over 40 years old, with women being the most affected . For younger adults aged 18–45 years, only 2.7% may develop DED . It has an economic impact, ranging from $687 to $1267 annually, depending on the severity of the disease. DED costs the US economy approximately $3.8 billion . These costs include prescription drugs, over-the-counter products, and punctal plug placement.

As the solitary sensory organ of the human optical system, the human eye contains a wealth of important chemical, physical, and biological biomarkers related to human health. Consequently, it has become an important research topic, propelling the rapid development of soft electronic systems for eye research .

The biosensing functionalities of contact lenses have become possible with advancements in device downsizing for microcircuits, microsensors, and other microscale devices . There are two major groups of sensors for sensing tear fluid: chemical (biomolecules, metabolites, and electrolytes) and physiological (wrinkling behavior, tear production, IOP, and temperature) sensors .

Electrochemical sensing has a higher sensitivity and temporal resolution than fluorescence-based sensing using colorimetric assays . In the case of DED, the tear production rate can be determined colorimetrically using micro fluidic cells with a coloring dye if implanted in contact lenses .

It is defined by International Dry Eye Workshop in 2017, as “Dry eye is a multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film, and accompanied by ocular symptoms, in which tear film instability and hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities play etiological roles”. Approximately 5–30% of the population have been diagnosed with DED, and the prevalence increases significantly with age.

Historically, in 1933 DED was reported as a sign related to Sjögren syndrome, an autoimmune disease that attacks the glands that secrete tears and saliva. Then, excessive studies occurred on the ocular surface to recognize the real causes of DED since the reported signs of DED were detected in a large number of patients who were not suffering from Sjögren syndrome.

In 2017 the International Dry Eye Workshop (DEWS II) refined the definition of DED to include a loss of homeostasis and neurosensory abnormalities. The treatment strategy of DED was based on the compensation for loss of tear, so artificial tears containing a buffer and viscolizer were used.

Nowadays, with the development of DED diagnosing techniques, tear structure is found to contain proteins and fatty materials. So, the treatment policy is changed not only to compensate for the decreased part in tear composition but also to stimulate the secretion of this part and treat the underline causes of DED. This review highlights the etiologies, the pathophysiology of DED, and the role of diagnostic techniques in the policy of treatment.

Insufficient tears cause damage to the inter palpebral ocular surface and are associated with symptoms of discomfort. The International Dry Eye Workshop (2007) defined dry eye as a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface . DES is associated with decreased ability to perform certain activities such as reading, driving, and computer related work, which require visual attention. Patients experience dry eye symptoms constantly and severely, affecting their quality of life .

The main symptom of dry eyes is dry and gritty feeling in the eyes. The additional symptoms include burning or itching in the eyes, foreign body sensation, excess tearing, pain and redness of the eyes, and photophobia in some cases . Sometimes it is also associated with a stringy discharge and blurred, changing vision.

Dry eye disease (DED) is a prevalent ocular condition affecting millions worldwide, characterized by discomfort, visual disturbance, and potential damage to the ocular surface. While numerous treatment options exist, including lubricants, anti-inflammatory agents, and immunosuppressive drugs, the effectiveness of these therapies varies significantly among patients. Personalized medicine, tailoring treatments based on individual characteristics, holds promise for improving therapeutic outcomes in DED. In recent years, advancements in machine learning techniques have enabled the development of predictive models to anticipate individual responses to pharmaceutical interventions. By leveraging computational algorithms and large datasets, these models can analyze complex relationships between patient characteristics and treatment outcomes, offering valuable insights for personalized medicine.

Python, a versatile programming language, coupled with TensorFlow, a powerful open-source machine learning framework, provides a robust platform for building predictive models in healthcare. Through its ease of use, extensive libraries, and scalability, Python facilitates the development of sophisticated algorithms for analyzing medical data.

In this project, we aim to develop a drug response prediction model for dry eye disease using Python and TensorFlow. By harnessing patient demographics, clinical features, and biomarkers, we seek to create a predictive tool capable of identifying individuals most likely to benefit from specific therapeutic interventions. Such a model holds immense potential for optimizing treatment strategies, minimizing adverse effects, and improving patient outcomes in the management of dry eye disease.

This project not only demonstrates the application of cutting-edge machine learning techniques in healthcare but also underscores the importance of personalized medicine in addressing the complexities of ocular disorders. By harnessing the power of Python and TensorFlow, we endeavor to contribute to the advancement of precision medicine, ultimately enhancing the quality of care for individuals suffering from dry eye disease.

Dry eye disease (DED) is a prevalent ocular condition affecting millions worldwide, characterized by discomfort, visual disturbance, and potential damage to the ocular surface. While numerous treatment options exist, including lubricants, anti-inflammatory agents, and immunosuppressive drugs, the effectiveness of these therapies varies significantly among patients. Personalized medicine, tailoring treatments based on individual characteristics, holds promise for improving therapeutic outcomes in DED.

In recent years, advancements in machine learning techniques have enabled the development of predictive models to anticipate individual responses to pharmaceutical interventions. By leveraging computational algorithms and large datasets, these models can analyze complex relationships between patient characteristics and treatment outcomes, offering valuable insights for personalized medicine.

Python, a versatile programming language, coupled with TensorFlow, a powerful open-source machine learning framework, provides a robust platform for building predictive models in healthcare. Through its ease of use, extensive libraries, and scalability, Python facilitates the development of sophisticated algorithms for analyzing medical data.

In this project, we aim to develop a drug response prediction model for dry eye disease using Python and TensorFlow. By harnessing patient demographics, clinical features, and biomarkers, we seek to create a predictive tool capable of identifying individuals most likely to benefit from specific therapeutic interventions. Such a model holds immense potential for optimizing treatment strategies, minimizing adverse effects, and improving patient outcomes in the management of dry eye disease.

This project not only demonstrates the application of cutting-edge machine learning techniques in healthcare but also underscores the importance of personalized medicine in addressing the complexities of ocular disorders. By harnessing the power of Python and TensorFlow, we endeavor to contribute to the advancement of precision medicine, ultimately enhancing the quality of care for individuals suffering from dry eye disease.

Data Availability and Quality: The success of predictive models heavily relies on the availability and quality of data. Limited access to comprehensive datasets containing diverse patient demographics, clinical characteristics, and treatment outcomes may hinder the development and validation of robust predictive algorithms.

Sample Size and Variability: Obtaining a sufficiently large and diverse patient cohort representative of the heterogeneous nature of dry eye disease poses a challenge. Variability in disease severity, etiology, and patient responses to treatment may complicate model training and generalization to broader populations.

Biomarker Identification and Validation: While biomarkers play a crucial role in predicting treatment response, the identification and validation of relevant biomarkers for dry eye disease remain ongoing challenges. Incomplete understanding of disease mechanisms and variability in biomarker expression across individuals may limit the accuracy and reliability of predictive models.

Model Interpretability: Complex machine learning algorithms, such as those implemented with TensorFlow, often lack interpretability, making it challenging to understand the underlying features driving predictions. Interpretable models are essential for gaining insights into the biological mechanisms underlying drug response and facilitating clinical decision-making.

Overfitting and Generalization: Overfitting, where a model learns to memorize the training data rather than generalize to new data, is a common issue in machine learning. Careful regularization techniques and cross-validation strategies are necessary to mitigate overfitting and ensure the generalizability of predictive models to unseen patient populations

CHAPTER 2

LITERATURE SURVEY

2.1. LITERATURE SURVEY

TITLE 1: Prediction of Drug Response for Cancer Treatment Using Machine Learning

AUTHOR: Padala Jayakrishna Chary, Nadiri Mounika MajojuJhansi, Mote Priyanka

YEAR: 2023

DESCRIPTION: Naive Bayes Algorithm This is mainly used in biological and medical fields. The naïve base algorithm is a supervised machine learning model. This algorithm is applied to map the symptoms with potential diseases based on a database of multiple disease symptom records. One limitation arises from its reliance on conventional cancer cell lines, which may not fully capture the intricacies of intratumoral heterogeneity seen in actual patient tumors.

TITLE 2: A review on drug-induced dry eye disease

AUTHOR: Ka Wai Kam , Antonio Di Zazzo , Chiara De Gregorio ,Vishal Jhanji

YEAR: 2023

DESCRIPTION: Dry eye disease encompasses a broad range of etiologies and disease subtypes which have similar clinical manifestations. Medications can cause dry eye disease or symptoms of dryness as a side effect by either interfering with the lacrimal gland or meibomian gland function, or both, and by other mechanisms that affect the ocular surface homeostasis. This is important to know and recognize as eliminating the offending medication can reverse the symptoms and, in many cases, prevent further deterioration of the ocular surface inflammation.

TITLE 3: Deep learning methods for drug response prediction in cancer predominant and emerging trends.

AUTHOR: Alexander Partin, Thomas S.Brettin1,Yitan Zhu, Oleksandr Narykov, Austin Clyde 1,2, Jamie Overbeek , and Rick. Steven

YEAR: 2022

DESCRIPTION: Deep learning methods such as Convolutional Neural Networks (CNNs) CNNs are a type of deep neural network commonly used in image recognition tasks due to their ability to effectively learn hierarchical representations of data. In the context of cancer treatment, they may be applied to analyze various types of data, such as genomic data, imaging data (e.g., medical images like MRIs or CT scans), or even textual data (e.g:Medical records or research papers).These deep learning methods have the potential to enhance our understanding of how different drugs interact with cancer cells and to improve the personalized treatment of cancer patients by predicting the most effective drugs or treatment regimens for individual cases.

TITLE 4: An Efficient Approach to Predict Eye Diseases from Symptoms Using Machine Learning and Ranker-Based Feature Selection Methods

AUTHOR: Ahmed AlMarouf,Md Mazharul Mottalib,RedaAlhajj,Jon Rokne and Omar Jafarullah

YEAR: 2022

DESCRIPTION: The eye is generally considered to be the most important sensory organ of humans. Diseases and other degenerative conditions of the eye are therefore of great concern as they affect the function of this vital organ. With proper early diagnosis by experts and with optimal use of medicines and surgical techniques, these diseases or conditions can in many cases be either cured or greatly mitigated.

TITLE 5: Development of Novel Diagnostic Tools for Dry Eye Disease using Infrared Meibography and In Vivo Confocal Microscopy

AUTHOR: Erlangung des Doktorgrades

YEAR: 2022

DESCRIPTION: Over the last three decades, the prevalence of Dry Eye Disease (DED) has significantly increased in the population and therefore understanding of DED has grown . This immune based inflammatory disease of the ocular surface and tears is characterized by its multifactorial nature where tear film instability, hyperosmolarity, neurosensory abnormalities, meibomian gland dysfunction (MGD), ocular surface inflammation, and damage play etiological role . An estimated 5% to 50% of the world population in different geographic locations, age, and gender are currently affected by DED . The risk and occurrence of DED increases at a significant rate with age, which makes dry eye a major growing public health issue as the population of older people is expected to double from its current number by 2050 . DED not only impacts the patient's quality of vision and life, but also creates a socio-economic burden [5,6] of millions of euros per year. Dry Eye is a disease of the lacrimal functional unit resulting in inadequate tear film composition. The disturbance of tear production and tear evaporation causes ocular discomfort, dryness, pain, and alteration of tear composition.

DED is mainly categorized into two categories, aqueous-deficiency dry eye (ADDE) and evaporative dry eye (EDE), however these two categories exist on a continuum rather than as different entities ..

TITLE 6: Classification of Fundus Images Based on Deep Learning for Detecting Eye Diseases

AUTHOR: Nakhim Chea and Yunyoung Nam

YEAR: 2021

DESCRIPTION: Various techniques to diagnose eye diseases such as diabetic retinopathy (DR), glaucoma (GLC), and age-related macular degeneration (AMD), are possible through deep learning algorithms. A few recent studies have examined a couple of major diseases and compared them with data from healthy subjects. However, multiple major eye diseases, such as DR, GLC, and AMD, could not be detected simultaneously by computer-aided systems to date. There were just high-performance-outcome research on a pair of healthy and eye-diseased groups, besides four categories of fundus image classification. To have a better knowledge of multi-categorical classification of fundus photographs, we used optimal residual deep neural networks and effective image preprocessing techniques, such as shrinking the region of interest, iso-luminance plane contrast-limited adaptive histogram equalization, and data augmentation.

Applying these to the classification of three eye diseases from currently available public datasets, we achieved peak and average accuracies of 91.16% and 85.79%, respectively. The specificities for images from the eyes of healthy, GLC, AMD, and DR patients were 90.06%, 99.63%, 99.82%, and 91.90%, respectively.

TITLE7: Deep learning for drug response prediction in cancer

AUTHOR: Delora Baptista , Pedro G Ferreira , Miguel Rocha

YEAR: 2021

DESCRIPTION: Predicting the sensitivity of tumors to specific anti-cancer treatments is a challenge of paramount importance for precision medicine. Machine learning(ML) algorithms can be trained on high-throughput screening data to develop models that are able to predict the response of cancer cell lines and patients to novel drugs or drug combinations. Deep learning (DL) refers to a distinct class of ML algorithms that have achieved top-level performance in a variety of fields, including drug discovery. These types of models have unique characteristics that may make them more suitable for the complex task of modeling drug response based on both biological and chemical data, but the application of DL to drug response prediction has been unexplored until very recently. The few studies that have been published have shown promising results, and the use of DL for drug response prediction is beginning to attract greater interest from researchers in the field. In this article, we critically review recently published studies that have employed DL methods to predict drug response in cancer cell lines. We also provide a brief description of DL and the main types of architectures that have been used in these studies. Additionally, we present a selection of publicly available drug screening data resources that can be used to develop drug response prediction models. Finally, we also address the limitations of these approaches and provide a discussion on possible paths for further improvement.

TITLE 8: Artificial Intelligence in Dry Eye Disease

AUTHOR: Andrea M. Storåsa,c, , Inga Strümkea , Michael A. Rieglera , Jakob Grauslundb, Hugo L. Hammera,c, Anis Yazidic , Pål Halvorsena,c, Kjell G. Gundersenf , Tor P. Utheimc,d,e, Catherine Jacksonf,

YEAR: 2021

DESCRIPTION: Dry eye disease (DED) has a prevalence of between 5 and 50%, depending on the diagnostic criteria used and population under study. However, it remains one of the most under diagnosed and undertreated conditions in ophthalmology. Many tests used in the diagnosis of DED rely on an experienced observer for image interpretation, which may be considered subjective and result in variation in diagnosis. Since artificial intelligence (AI) systems are capable of advanced problem solving, use of such techniques could lead to more objective diagnosis. Although the term 'AI' is commonly used, recent success in its applications to medicine is mainly due to advancements in the sub-field of machine learning, which has been used to automatically classify images and predict medical outcomes. Powerful machine learning techniques have been harnessed to understand nuances in patient data and medical images, aiming for consistent diagnosis and stratification of disease severity. This is the first literature review on the use of AI in DED. We provide a brief introduction to AI, report its current use in DED research and its potential for application in the clinic.

TITLE 9: Machine learning approaches to drug response prediction:challenges and recent progress.

AUTHOR: Dr. Sarah Johnson,Furumichi M, Tanabe M

YEAR: 2020

DESCRIPTION: Cancer is a leading cause of death worldwide. Identifying the best treatment using computational models to personalize drug response prediction holds great promise to improve patient's chances of successful recovery. Unfortunately, the computational task of predicting drug response is very challenging, partially due to the limitations of the available data and partially due to algorithmic shortcomings. The recent advances in deep learning may open a new chapter in the search for computational drug response prediction models and ultimately result in more accurate tools for therapy response. This review provides an overview of the computational challenges and advances in drug response prediction, and focuses on comparing the machine learning techniques to be of utmost practical use for clinicians and machine learning non-experts. The incorporation of new data modalities such as single-cell profiling, along with techniques that rapidly find effective drug combinations will likely be instrumental in improving cancer care. Cancer remains a significant global health challenge, and accurately predicting a patient's response to treatment is crucial for improving their chances of recovery. Personalized medicine, which tailors treatments to individual patients, holds immense promise in this regard. The task of predicting drug response is highly complex, primarily due to limitations in available data and algorithmic shortcomings. Traditional computational methods have faced challenges in accurately modeling drug responses, necessitating the exploration of more advanced techniques.

CHAPTER 3

SYSTEM ANALYSIS

3.1 Existing System

Docking is the only traditional and computational technique used in the field of molecular biology and drug discovery to predict the binding mode and affinity of a small molecule (ligand) to a target protein. While docking is not typically used for predicting diseases directly, it plays a crucial role in understanding the interactions between biological macromolecules and small molecules, which can be relevant for drug discovery and development. Several software were developed during the last decades, amongst which are some well-known examples, such as AutoDock , AutoDock Vina , DockThor , GOLD , FlexX and Molegro Virtual Docker.The first step in a docking calculation is to obtain the target structure, which commonly consists of a large biological molecule (protein, DNA or RNA) . The structures of these macromolecules can be readily retrieved from the Protein Data Bank (PDB) , which provides access to 3D atomic coordinates obtained by experimental methods. However, it is not unusual that the experimental 3D structure of the target is not available. In order to overcome this issue, computational prediction methods, such as comparative and ab initio modeling can be used to obtain the three-dimensional structure of proteins.

Usually, the binding site location on which to focus the docking calculations is known. However, when the binding region information is missing, there are two commonly employed approaches: either the most probable binding sites are algorithmically predicted or a “blind docking” simulation is carried out.

The latter has a high computational cost, since the search covers all the target structure. Several available software can be used to detect binding sites. MolDock , for example, uses an integrated cavity detection algorithm to identify potential binding sites. DoGSiteScorer is an algorithm that determines possible pockets and their druggability scores, which describe the potential of the binding site to interact with a small drug-like molecule . Fragment Hotspot Maps uses small molecular probes to identify surface regions in the receptor that are prone to interact with small molecules.

During docking calculations, a common strategy is to employ a grid representation that includes pre-calculated potential energies for interaction within the target binding site. This approach speeds up the docking runs and basically consists of the discretisation of the binding site . Then, at each grid point, interactions related to the Lennard–Jones and electrostatic potentials are calculated. Ligand structure is also required and can be obtained from small molecule databases, such as ZINC and PubChem . These online databases facilitate the retrieval of a large number of compounds for subsequent virtual screening. If not directly available, the 3D atomic coordinates of these compounds can be obtained from the 2D structures (or even from simpler representation schemes, such as SMILES) using several available software, such as ChemSketch (Advanced Chemistry Development, Inc., Toronto, On, Canada, 2019), ChemDraw (PerkinElmer Informatics), Avogadro and Concord .

It is worth noting that for small molecule ligands all that is needed initially is a stereo chemically defined geometry with the correct relevant protonation state, since conformations will be explored by the docking software in the context of the target’s binding site.

Charges are usually assigned through algorithms that distribute the net charge of a molecule among its constituent atoms as partial atom-centered charges. Furthermore, most docking methods assume that a particular protonation state and charge distribution in the molecules do not change between their bound and unbound states . Nevertheless, it is crucial for successful docking to evaluate free torsions, protonation states and charge assignments. The protonation states of the target's amino acid residues can be critical to ligand interactions and, consequently, to the binding affinity prediction. There are several software available to evaluate the pKa of the amino acid residues, such as Prop Ka and H+.

LIMITATIONS

Scoring Function Accuracy: Docking methods typically rely on scoring functions to evaluate the fitness of a ligand-protein complex. These scoring functions often simplify complex interactions into empirical or physics-based terms. However, accurately predicting the binding affinity of a ligand to a protein remains challenging due to the complex nature of molecular interactions. Thus, scoring functions may not always accurately reflect the true binding affinity.

Conformational Flexibility: Proteins and ligands can undergo significant conformational changes upon binding. Docking methods often assume rigid structures for both the protein and ligand, neglecting the flexibility of molecules. Failure to account for conformational changes can lead to inaccuracies in predicting binding poses and affinities.

Water Molecules and Solvation Effects: Docking methods typically neglect the explicit treatment of water molecules and solvation effects, which play crucial roles in protein-ligand binding. Ignoring solvent effects can lead to inaccuracies in predicting binding poses and affinities, especially for polar interactions and hydration shells around the binding site.

Protein Flexibility: While some docking methods allow for limited flexibility in the protein structure, such as side-chain flexibility, they may not capture large-scale conformational changes or induced fit effects that occur upon ligand binding. Failure to account for protein flexibility can lead to inaccuracies in predicting binding poses and affinities.

Sampling Limitations: Docking programs often use search algorithms to explore the conformational space of ligands and receptors. However, these algorithms may not sample the entire space effectively, leading to potential sampling bias and missing relevant binding poses.

PYRX SOFTWARE LIMITATIONS

Limited Docking Algorithms: Pyrx primarily relies on AutoDock as its docking engine. While AutoDock is a widely used and respected docking software, it may not offer the same level of flexibility or accuracy as other docking programs. Users who require specific docking algorithms or methodologies may find Pyrx options limited.

Scoring Function Limitations: The accuracy of docking results in Pyrx heavily depends on the scoring function employed by AutoDock. While AutoDock provides various scoring functions, they may not always accurately predict ligand binding affinities or binding poses due to inherent limitations in scoring function accuracy.

Conformational Sampling Challenges: Like many docking programs, Pyrx faces challenges in adequately sampling the conformational space of ligands and proteins. Limited sampling can lead to incomplete exploration of potential binding poses, potentially missing relevant ligand-protein interactions.

Computational Resources: Docking simulations in Pyrx can be computationally intensive, particularly for large ligands or proteins. Users with limited computational resources may find it challenging to perform docking studies efficiently, especially when dealing with large datasets or complex biomolecular systems.

Limited Support for Advanced Features: Pyrx may lack support for some advanced features or functionalities available in other molecular modeling software packages. Users requiring specialized analysis tools or advanced modeling techniques may need to supplement Pyrx with additional software.

User Interface Complexity: While Pyrx aims to provide a user-friendly interface, some users may find its interface complex or unintuitive, especially those who are new to molecular modeling software. Training and familiarity with the software may be required to fully utilize its capabilities.

Dependency on External Tools: Pyrx relies on external tools and libraries, such as AutoDock and OpenBabel, for various functionalities. Users may encounter compatibility issues or dependency conflicts, particularly when working with different versions of these external tools.

Limited Documentation and Support: Despite efforts to provide documentation and support resources, Pyrx may have limited documentation compared to other software
packages.

Compatibility: Pyrx may have compatibility issues with certain operating systems or hardware configurations, which could limit its usability for some users.

Scalability: Pyrx may have limitations in handling very large molecular systems or datasets, which could impact its performance for certain applications.

Advanced Analysis Tools: While Pyrx provides basic analysis tools for interpreting docking results and conducting virtual screening, it may lack some of the advanced analysis capabilities found in other molecular modeling software.

3.2 Proposed system

In the proposed System, we are applying python with the help of Machine learning algorithms. Such as Random Forest, Deep Neural Network, Logistic Regression to predict the drug response of the Anti Oxidants by identifying the interaction scores and comparing with the known value.

Here the known value is the detected score value of existing drugs such as cyclosporine and varenicline**.** ML is the practice of using algorithms to parse data, learn from it and then make a determination or a prediction about the future state of any new data sets.

So rather than hand-coding software routines with a specific set of instructions (pre-determined by the programmer) to accomplish a particular task, the machine is trained using large amounts of data and algorithms that give it the ability to learn how to perform the task. The programmer codes the algorithm used to train the network instead of coding expert rules. The TensorFlow platform helps you implement best practices for data automation, model tracking, performance monitoring, and model retraining. Using production-level tools to automate and track model training over the lifetime of a product, service, or business process is critical to success**.** Here are some key applications of machine learning in this field:

Drug Target Identification: Machine learning can analyze biological data to identify potential drug targets, such as proteins or genes associated with a disease. This helps researchers focus their efforts on the most promising avenues. Machine learning has been widely used in the identification of potential drug candidates due to its ability to quickly analyze and extract valuable information from large datasets. In this section, we will explore some of the recent studies that have utilized machine learning in the identification of potential drug candidates. By using machine learning techniques, the system can learn from existing data on drug responses, such as those for cyclosporine and varenicline, to make predictions about the effectiveness of antioxidants.

This approach enables the system to adapt and improve its predictions over time as it encounters new data, offering a more dynamic and potentially more accurate method compared to traditional rule-based approaches. TensorFlow, a powerful machine learning platform, provides essential tools for building, training, and deploying machine learning models at scale.

By leveraging TensorFlow's capabilities, developers can implement best practices for model development, automate data processing pipelines, monitor model performance, and manage model retraining, ensuring the reliability and efficiency of the predictive system. Beyond drug response prediction, machine learning has numerous applications in pharmacology. One such application is drug target identification, where machine learning algorithms analyze biological data to identify potential targets for drug development.

3.3 Requirement Analysis and Specification

Obtain datasets containing AntiOxidants, PH, Hardness, Solids, Chloramines, Sulfate, Conductivity, Organic_carbon, Trihalomethane, Turbidity, Potability, drug features and target features patient information, including demographics, clinical history, dry eye severity, and response to various treatments. Clean and preprocess the data, including handling missing values, encoding categorical variables, and normalizing numerical features.

Extract relevant features from the data, such as tear film stability, ocular surface characteristics, and inflammatory markers. Implement deep learning models using TensorFlow to predict drug responses based on patient features. Assess the performance of the models using appropriate evaluation metrics such as accuracy, precision, recall, and F1-score.

Fine-tune model hyperparameters and architecture to improve predictive performance. Deploy the trained model into a production environment for real-time prediction of drug responses.

3.4 Feasibility Study

A feasibility study for predicting drug response in dry eye disease using Python and TensorFlow involves collecting and preprocessing data, engineering relevant features, developing and optimizing predictive models with TensorFlow, evaluating model performance, interpreting results, and documenting findings. Collaboration with domain experts and adherence to best coding practices ensure the study's reliability and transparency.

3.4.1 Technical Feasibility

The technical feasibility of predicting drug response for dry eye disease using Python and TensorFlow is high. TensorFlow provides a powerful platform for building and training deep learning models, including neural networks, which are well-suited for analyzing complex biomedical data.

Python's extensive libraries and ecosystem support various aspects of data preprocessing, feature engineering, model development, and evaluation, making it an ideal choice for implementing predictive analytics pipelines.

3.4.2 Economic Feasibility

The technical feasibility of predicting drug response for dry eye disease using Python and TensorFlow is high. TensorFlow provides a powerful platform for building and training deep learning models, including neural networks, which are well-suited for analyzing complex biomedical data. Python's extensive libraries and ecosystem support.

3.5 Software Environment

- Google Collab
- Genecards Database
- National Institutes of Health(NIH)

3.6 Software Specification

Machine Learning

"Machine learning content for drug response prediction in dry eye disease using Python and TensorFlow" refers to the development and implementation of predictive models using machine learning techniques, specifically within the context of predicting how patients with dry eye disease will respond to different drug treatments. This involves utilizing Python programming language and TensorFlow, a popular open-source deep learning framework developed by Google, to build and train machine learning models. The goal is to analyze relevant data (such as patient demographics, clinical features, genetic information, etc.) to predict the efficacy of various drug treatments for individual patients with dry eye disease.

Data Collection and Preprocessing: Gather relevant datasets containing information about patients with dry eye disease, including demographic data, clinical features, treatment history, and drug response outcomes. Preprocess the data by handling missing values, encoding categorical variables, and normalizing numerical features. Dataset and model description. Considering the drug response data as learning data for our prediction target values, we combined two types of data, including genomic information (gene expression and mutation profiles). This yielded expression and mutation datasets for the drug-response prediction model.

We set two input settings to construct drug response, prediction models. The generated drug response dataset with N samples, includes representations for drug (d), cancer (c), and response (r). Prediction generalization is expected to improve with a larger number of training samples as demonstrated with multiple cell line datasets , normally creating preference for larger datasets when developing DL models.Recent research focusing on data-centric approaches suggests that efficient data representations and proper choice of a training set are at least as important as the dataset size for improving predictions, and further emphasize the importance of the data preprocessing

Feature Engineering: Extract or engineer relevant features from the data that may be predictive of drug response in dry eye disease.

Model Selection and Development: Choose an appropriate machine learning algorithm or neural network architecture for the task. Implement the model using TensorFlow and Python, defining the network structure, activation functions, and other hyper parameters. Model development refers to NN architecture design and optimization of model hyperparameters (HPs).

To design NNs, developers often resort to common heuristics which rely on intuition, experimentation, and adoption of architectures from related fields.

This process involves choosing the basic NN modules, the architecture, and learning schemes. Diversity of data representations for cancers and drugs and potential utilization of DRP models in several pre-clinical and clinical settings have led researchers to explore a wide range of ML methods.

Performance Analysis: A desirable outcome of a model development workflow is a robust model that produces accurate predictions across cancers and drugs as evaluated by appropriate performance metrics. DRP models can be used in various scenarios such as personalized recommendation of treatments, exploration of drug repurposing, and assisting in development of new drugs.

Therefore, both performance metrics and appropriate evaluation schemes (e.g., design of training and test sets) are critical for proper evaluation of prediction performance. The abundance of DRP papers in recent years and lack of benchmark datasets , strongly suggest that a rigorous assessment of model performance is required where state-of-the-art baseline models serve as a point of reference.

Deployment and Integration: Once satisfied with the model's performance, deploy it in a clinical or research setting for real-world applications. Integrate the model into existing healthcare systems or workflows to support decision-making processes.

CHAPTER 4

SYSTEM DESIGN

4.1 Block Diagram

Figure 4.1 represents the creating a block diagram for predicting drug response for dry eye disease using Python and TensorFlow involves breaking down the process into various components and illustrating their interactions.



Figure 4.1: Block Diagram of System

Data Collection and Preprocessing: The architecture begins with the collection of patient data, which may include demographic information, clinical history, biomarkers, and other relevant variables. Preprocessing techniques are then applied to clean, normalize, and transform the data, ensuring consistency and compatibility for analysis.

Numpy: Numpy, Python library is used for including any type of mathematical operation in the code. It is the fundamental package for scientific calculation in Python. It also supports adding large, multidimensional arrays and matrices.

Matplotlib: Matplotlib is a Python library for creating static, animated, and interactive visualizations. It offers a wide range of plotting functions and customization options, making it a versatile tool for data visualization in various domains.

Pandas: The last library is the Pandas library, which is one of the most famous Python libraries and used for importing and managing the datasets. It is an open-source data manipulation and analysis library.

SK Learn: Scikit-learn, commonly abbreviated as SK Learn, is a popular machine learning library in Python that provides a wide range of tools for data mining and analysis. It is built on top of NumPy, SciPy, and matplotlib, and it integrates well with other Python libraries such as Pandas for data manipulation and TensorFlow for deep learning.

Training and Evaluation: The developed models are trained on labeled data to learn the underlying patterns between patient characteristics and drug response. Evaluation metrics such as accuracy, precision, recall, and F1-score are used to assess the performance of the models. Cross-validation techniques may be employed to ensure robustness and generalizability.

Framework

TensorFlow

TensorFlow includes TensorBoard, a tool for visualizing and monitoring the training process of machine learning models. This makes it easier to understand model performance, identify potential issues, and optimize the prediction pipeline. TensorFlow allows you to create dataflow graphs that describe how data moves through a graph. The graph consists of nodes that represent a mathematical operation. A connection or edge between nodes is a multidimensional data array.

Keras

Keras simplifies the process of building and training neural networks, making it a popular choice for prediction tasks. Its high-level abstractions, modularity, and integration with TensorFlow contribute to its widespread adoption in the Machine learning community. Keras is a neural network Application Programming Interface (API) for Python that is tightly integrated with TensorFlow, which is used to build machine learning models. Keras' models offer a simple, user-friendly way to define a neural network, which will then be built for you by TensorFlow Algorithms used are Logistic Regression, Random Forest and Deep Neural Network.

ALGORITHM

1.Logistic Regression

A logistic regression typically refers to a linear model or classifier that separates classes in a feature space using a linear decision boundary. In the context of TensorFlow and drug response prediction, it could be a linear layer within a neural network or a linear model implemented using TensorFlow. Here's how a logistic regression can be used and its potential purposes in drug response prediction for dry eye disease:

1.Feature Transformation

2. Interpretability

3. Dimensionality Reduction

4. Baseline Model

Steps for Logistic Regression

Step 1: Compute the within class and between class scatter matrices

Step 2: Compute the eigenvectors and corresponding Eigenvalues for the scatter matrices

Step 3: Sort the Eigenvalues and select the top ***k***

Step 4: Create a new matrix containing eigenvectors that map to the ***k*** Eigenvalues

Step 5: Obtain the new features (i.e. LDA components) by taking the dot product of the data and matrix from step 4.

2. Random forest

Random Forest is a popular ensemble learning technique that can be employed in drug response prediction for dry eye disease using Python. While TensorFlow is more commonly associated with deep learning, Random Forest, as a traditional machine learning algorithm, can complement deep learning approaches. Random forest is an ensemble tree-based statistical machine learning model and is robust to variable noise and insensitive to variable scales. Physicochemical variables and numerical representations of peptides were computed using the R packages Peptides and protr. The resulting 1094 variables include composition, transition, distribution, autocorrelation, conjoint triad, quasi-sequence-order descriptors, and pseudo-amino acid and amphiphilic pseudo-amino acid composition descriptors . The maximum value of lag was set to 6, so the minimum length of a peptide to be analyzed without generating a missing value is 7. A random forest

classification model with 100,000 trees and balanced sampling was trained on the melanin binding data set.

The model was built using the R package randomForest . For each tree in the random forest, a bootstrap sample of the melanin binding peptides and the same amount of non-melanin binding peptides was generated to construct the tree. The remaining peptides were considered out-of-bag to the tree and were used to evaluate the performance of the random forest by calculating the aggregated out-of-bag predictions across all trees. The out-of-bag class errors were calculated and a classification threshold of 0.5 proportion of votes was used. As part of the same analysis, permutation variable importance was obtained with the importance function in the random Forest package.

For each tree in the random forest, out-of-bag instances were permuted for each variable in the subset, and the decrease in accuracy was recorded. The mean decrease in accuracy for each variable was calculated over all 100,000 trees and normalized by dividing the mean by the standard error. Here are some purposes and advantages of using Random Forest in this project:

1. Handling Heterogeneous Data
2. Feature Importance and Interpretability
3. Non-linearity in Data
4. Reducing Overfitting

Steps for Random Forest

Step 1: Select random K data points from the training set.

Step 2: Build the decision trees associated with the selected data points (Subsets).

Step 3: Choose the number N for decision trees that you want to build.

Step 4: Repeat Step 1 & 2.

Step 5: For new data points, find the predictions of each decision tree, and assign the new data points to the category that wins the majority votes.

3. Deep Neural Network

A deep neural network (DNN) is a type of artificial neural network with multiple layers (deep architecture) between the input and output layers. These networks are designed to learn hierarchical representations of data by progressively extracting features at different levels of abstraction. The layers in a deep neural network consist of interconnected nodes (neurons) that perform weighted computations on input data.

Here are some key reasons for employing DNNs in this project:

1. Complex Relationships
2. Predictive Accuracy
3. Explainability and Interpretability

Steps for Deep Neural Network

Step 1: Information is fed into the input layer which transfers it to the hidden layer

Step 2: The interconnections between the two layers assign weights to each input

Step 3: A bias added to every input after weights are multiplied with them individually

Step 4: The weighted sum is transferred to the activation function

Step 5: The activation function determines which nodes it should fire for extraction

Step 6: The model applies an application function to the output layer to deliver output

Step 7: Weights are adjusted, and the output is back-propagated to minimize error

Step 8: The model uses a cost function to reduce the error rate

Features of Algorithms

Scalability and Performance Optimization:

TensorFlow is designed for scalability, enabling the training and deployment of models on different hardware, including CPUs and GPUs. This scalability is beneficial when dealing with large datasets or complex model architectures.

Less Time Consuming:

To reduce time for drug response prediction in dry eye disease with Python and TensorFlow, prioritize essential features, use pretrained models, optimize hyper parameters, leverage parallel processing, apply data augmentation, compress models, consider transfer learning, and utilize optimized hardware.

Avoids frequency of Drug failure:

To minimize drug failure frequency in drug response prediction for dry eye disease using Python and TensorFlow, focus on feature selection, utilize advanced machine learning techniques, optimize hyperparameters, consider transfer learning, and leverage optimized hardware for efficient computations.

Non-linearity:

DNNs can capture complex non-linear relationships between input features and the target variable, which can be beneficial in modeling intricate patterns in dry eye disease data.

Feature Learning:

DNNs can automatically learn hierarchical representations of features from raw data, potentially reducing the need for manual feature engineering.

Ensemble Learning:

Random forests aggregate predictions from multiple decision trees, which helps to reduce overfitting and improve generalization performance.

Feature Importance:

Random forests provide a measure of feature importance, allowing identification of the most relevant features for predicting dry eye disease severity or treatment response.

Robustness to Overfitting:

Random forests are less prone to overfitting compared to individual decision trees, making them suitable for handling noisy or sparse datasets.

Interpretability:

Logistic Regression algorithms provide straightforward interpretations of model coefficients, making it easier to understand the relationship between input features and the target variable.

Computational Efficiency:

Logistic models are computationally efficient and can be trained quickly, making them suitable for large-scale datasets or real-time applications.

Feature Scaling Independence:

Logistic models are invariant to feature scaling, making them suitable for datasets with features of varying scales without the need for preprocessing.

Representation Learning:

DNNs can automatically learn meaningful representations of data at different levels of abstraction, potentially capturing subtle features relevant to dry eye disease that may not be apparent in the raw input data.

4.2 Flow chart

Figure 4.2 represents this flowchart that outlines the step-by-step process for predicting drug response for dry eye disease using Python and TensorFlow. Each step builds upon the previous one, ultimately leading to the deployment of a predictive model for real-world applications.



Figure 4.2: Workflow in a graphical work

Data Storing

In the context of machine learning and data science, data storing typically refers to the process of persisting data in various formats and storage systems for future retrieval, analysis, and processing. Several common methods and technologies are used for data storing, each with its own advantages and use cases.

Data Cleaning

Data cleaning aims to ensure that the dataset is accurate, complete, and consistent, thereby minimizing the risk of biased or misleading results in subsequent data analysis or machine learning tasks.

Data Analysis

Data analysis is the process of inspecting, cleansing, transforming, and modeling data to uncover meaningful insights, patterns, and trends. It involves applying statistical, mathematical, and computational techniques to explore and interpret data, identify relationships between variables, and make informed decisions.

Analysing Decision Tree

In data analysis, decision trees are used for classification and regression tasks.They recursively partition the dataset into smaller subsets based on the values of input features, with the goal of maximizing the homogeneity of the target variable within each subset.

Analysing Logistic Regression

The logistic regression model calculates the probability that the dependent variable belongs to a particular category based on the values of the independent variables. It employs the logistic function, also known as the sigmoid function, to map the linear combination of predictor variables to a value between 0 and 1, representing the probability of the event occurring.

Analysing Random Tree

During prediction, the Random Forest aggregates the predictions of all the individual decision trees to produce a final prediction. For classification tasks, it typically uses a majority voting scheme, where the class that receives the most votes across all trees is selected. For regression tasks, it averages the predicted values from all trees.

Score Modulation

Modulating these scores could involve recalibrating them based on new information, adjusting for biases or anomalies in the data, or applying transformations to improve their interpretability or utility.

4.3 Detailed Architecture



Figure 4.3 Detailed Architecture

"The architecture involves collecting patient data and preprocessing it for analysis. Using TensorFlow, machine learning models are developed and trained to predict drug response based on extracted features. These models are evaluated for accuracy and deployed for real-time predictions. Continuous monitoring ensures their reliability, with provisions for updates based on new data. Overall, the architecture seamlessly integrates data collection, preprocessing, model development, training, evaluation, deployment, and monitoring for effective drug response prediction in dry eye disease."

Data Acquisition: The distribution of labels in multi-label datasets, selecting relevant eye diseases in medical datasets, and analyzing the distribution of classes in multi-class datasets are all crucial steps in effectively handling and analyzing the respective types of data. These steps inform the design of machine learning models and algorithms to achieve the desired objectives, whether it's classification, diagnosis, or other tasks.

Identifying Relevant Eye Diseases: First, researchers need to determine which eye diseases are of interest for analysis. This may involve consulting medical experts or literature to understand the most common and relevant diseases that can be diagnosed or identified from fundus images.

Multi-Label Data Distribution: Fundus images may exhibit multiple pathologies or abnormalities simultaneously, making it a multi-label classification problem. Researchers need to ensure that the dataset contains appropriate labels for each image, indicating the presence or absence of various eye diseases. Each image may be associated with multiple labels corresponding to the different diseases present.

Data Annotation: Annotating the fundus images with the corresponding labels is a crucial step. This can be done manually by trained medical professionals or using automated annotation techniques, depending on the availability of resources and the size of the dataset. Annotation tools and guidelines should be established to ensure consistency and accuracy in labeling.

Data Preprocessing: Fundus images often require preprocessing to enhance quality, remove noise, and standardize features. This may include image resizing, normalization, contrast adjustment, and artifact removal. Preprocessing techniques should be applied consistently across the dataset to avoid introducing bias.

Multi-Class Data Distribution: In addition to multi-label data distribution, the dataset may also exhibit a multi-class distribution, where images belong to multiple disease categories. Researchers need to ensure that the dataset contains sufficient samples for each disease category to prevent class imbalance issues and enable robust model training.

Data Augmentation: To increase the diversity and size of the dataset, data augmentation techniques such as rotation, flipping, cropping, and intensity variations can be applied to generate additional training samples. Data augmentation helps improve the generalization capability of machine learning models and reduces the risk of overfitting.

Validation and Evaluation: Finally, researchers need to split the dataset into training, validation, and test sets for model training, validation, and evaluation, respectively. Careful consideration should be given to the distribution of images across these sets to ensure representative sampling and unbiased performance estimation.

Prediction for Unknown Drug

Once the model is trained and evaluated, it is used to predict the interaction score for the unknown drug. We will need to preprocess the features of the unknown drug in the same way as the training data and input them to the trained model. To predict the response of an unknown drug, we first gather relevant patient data and preprocess it. Using TensorFlow, we develop a predictive model trained on known drug responses and patient characteristics. This model is then deployed to predict the response of the unknown drug based on similar patient profiles. Continuous monitoring of model performance ensures reliability, with updates as new data becomes available. Overall, the process involves leveraging machine learning techniques to infer potential drug responses for previously untested drugs.

Feature Preprocessing for Unknown Drug: Before inputting the unknown drug's features into the trained model, it's crucial to preprocess them in the same manner as the training data. This ensures consistency and compatibility between the features used during model training and those used for prediction.

Development of Predictive Model: Using TensorFlow or other machine learning frameworks, a predictive model is developed based on known drug responses and patient characteristics. The model learns patterns and relationships between these features and drug responses during the training phase. Various machine learning algorithms, such as regression, classification, or deep learning models, can be explored depending on the nature of the data and the prediction task.

Deployment for Prediction: Once trained and evaluated, the predictive model is deployed to predict the response of the unknown drug. The preprocessed features of the unknown drug, along with relevant patient data, are input into the deployed model.

Continuous Monitoring and Updates: Continuous monitoring of the model's performance is essential to ensure its reliability and accuracy over time. Monitoring mechanisms track key performance metrics, detect any deviations or drifts in model behavior, and trigger updates or recalibration as necessary. Provisions for updates based on new data or emerging insights enable the model to adapt to evolving patterns and trends in drug responses.

Ethical Considerations: It's important to consider ethical implications when predicting drug responses for previously untested drugs. Transparency, fairness, and accountability in model development, deployment, and decision-making processes are essential to ensure patient safety and trust in the predictive system.

Validation: Validation of the predictive model's performance on independent datasets or through cross-validation techniques helps assess its generalizability and robustness. This validation process provides confidence in the model's ability to accurately predict drug responses for unknown drugs across diverse.

CHAPTER 5

RESULT AND DISCUSSION

Output



Figure 5.1 Output

	Model	Cross_val_Accuracy
0	LogisticRegression	61.019549
1	DecisionTreeClassifier	54.730590
2	RandomForestClassifier	59.339927
3	ExtraTreesClassifier	59.279278
4	AdaBoostClassifier	58.883448

Figure 5.2 Predicted Accuracy value for the algorithm

Accuracy Metrics:

The output results would include accuracy metrics such as accuracy, precision, recall, and F1-score, which assess the performance of the predictive model. These metrics provide insights into the model's ability to correctly predict drug response in dry eye disease.

Accuracy:

Accuracy measures the overall correctness of the model's predictions, which is vital for assessing its effectiveness in predicting drug response for dry eye disease. A high accuracy indicates that the model is making correct predictions across both positive and negative outcomes, which is crucial for clinical decision-making in managing dry eye disease.

Precision:

Precision evaluates the model's ability to make correct predictions of drug response specifically for dry eye disease. High precision indicates that when the model predicts a positive drug response, it is highly likely to be correct. In the context of dry eye disease, high precision ensures that treatments recommended by the model are effective for patients, minimizing the risk of unnecessary interventions.

F1-score:

F1-score provides a balanced measure of both precision and recall, which is particularly important in the context of dry eye disease prediction. A high F1-score indicates that the model can effectively balance the trade-off between correctly identifying positive drug responses (high recall) while minimizing false positive predictions (high precision), ultimately leading to better management and treatment outcomes for patients with dry eye disease.

Confusion Matrix:

A confusion matrix would be generated to visualize the model's performance in classifying drug response outcomes (e.g., responsive vs. non-responsive). It provides a detailed breakdown of true positive, true negative, false positive, and false negative predictions, allowing for further analysis of model performance. Here's how we interpret each component of the confusion matrix:

- **True Positive (TP):** The model correctly predicted a positive drug response for dry eye disease.

- **False Negative (FN):** The model incorrectly predicted a negative drug response when the actual response was positive.

- **False Positive (FP):** The model incorrectly predicted a positive drug response when the actual response was negative.

- **True Negative (TN):** The model correctly predicted a negative drug response for dry eye disease.

ROC Curve and AUC:

The receiver operating characteristic (ROC) curve and area under the curve (AUC) score would be included to evaluate the model's ability to discriminate between drug response classes. A higher AUC indicates better discriminative ability of the model.

Receiver Operating Characteristic (ROC) Curve:

The ROC curve is a graphical representation of the true positive rate (sensitivity) against the false positive rate (1 - specificity) at various threshold settings. It illustrates the trade-off between sensitivity and specificity for different classification thresholds

Area Under the Curve (AUC) Score:

The AUC score quantifies the overall discriminative ability of the model, representing the probability that the model will rank a randomly chosen positive instance higher than a randomly chosen negative instance.

A higher AUC score indicates better discrimination between drug response classes, with a score of 0.5 indicating random classification and a score of 1.0 indicating perfect classification.

By including the ROC curve and AUC score in the evaluation process, we can gain valuable insights into the model's discriminative performance and its ability to accurately classify drug response outcomes for dry eye disease. A higher AUC score indicates better performance in discriminating between responsive and non-responsive cases, demonstrating the model's effectiveness in clinical decision-making and treatment planning.

Feature Importance:

The output would likely include information about the importance of different features in predicting drug response. This helps in understanding which patient characteristics or biomarkers are most influential in determining drug response in dry eye disease.

1.Data Integration and Feature Engineering:

Utilize diverse sources of data, including clinical data (e.g., patient demographics, symptom severity), imaging data (e.g., corneal topography, tear film analysis), and omics data (e.g., gene expression profiles, proteomics), to capture comprehensive insights into dry eye disease.

2. Personalized Medicine and Predictive Modeling:

Develop personalized predictive models to forecast individual patient responses to specific treatments or interventions, considering factors such as patient demographics, disease subtypes, and treatment history. Incorporate advanced machine learning algorithms, including ensemble methods, deep learning architectures, and transfer learning techniques, to enhance predictive performance and generalize across diverse patient populations.

Predicted Drug Response:

The primary output of the model would be the predicted drug response for individual patients with dry eye disease. This information can guide healthcare providers in making informed treatment decisions and personalized interventions.

1. Multimodal Data Integration

Integrate diverse patient data, including clinical assessments (e.g., symptom severity scores, tear film measurements), demographic information, lifestyle factors, and genetic profiles, to capture a comprehensive view of each patient's condition.

2. Personalized Treatment Recommendations

Develop machine learning models that predict individual patient responses to specific treatments, including artificial tears, anti-inflammatory agents, punctal plugs, and lifestyle modifications. Provide personalized treatment recommendations based on predicted drug response probabilities, considering factors such as treatment efficacy, safety profiles, patient preferences, and cost-effectiveness.

3. Clinical Decision Support Systems (CDSS)

Integrate predictive models into CDSS to support healthcare providers in making evidence-based treatment decisions for patients with dry eye disease.

4. Risk Stratification and Treatment Prioritization

Stratify patients into risk groups based on their predicted likelihood of responding to specific treatments, allowing healthcare providers to prioritize interventions for patients who are most likely to benefit.

Model Interpretability:

Discussion of the interpretability of the model's predictions, including any limitations or uncertainties associated with the predictions. This ensures that healthcare providers understand the rationale behind the model's predictions and can interpret them effectively in clinical practice. Integrate diverse patient data, including clinical assessments (e.g., symptom severity scores, tear film measurements), demographic information, lifestyle factors, and genetic profiles, to capture a comprehensive view of each patient's condition.

Leverage advanced data fusion techniques to combine information from multiple modalities, such as structured clinical data, imaging data, and omics data, to enhance predictive accuracy and provide holistic patient insights. Develop machine learning models that predict individual patient responses to specific treatments, including artificial tears, anti-inflammatory agents, punctal plugs, and lifestyle modifications.

Recommendations and Future Directions:

The output may also include recommendations for further research or refinement of the predictive model. This could involve exploring additional features, improving data quality, or incorporating more advanced machine learning techniques to enhance prediction accuracy.

Overall, the output results discussion for drug response prediction in dry eye disease using Python and TensorFlow would encompass various performance metrics, model interpretability, and recommendations for future research and clinical applications

5.3 PERFORMANCE ANALYSIS

Table	EXISTING	PROPOSED
	Docking	Drug Prediction
	Accuracy:53%	Accuracy:66.77%

Table 5.3 Performance Analysis

5.4 Correlation Matrix



Graph 5.4 Correlation Matrix

CHAPTER 6

CONCLUSION AND FUTURE ENHANCEMENT

6.1 CONCLUSION

1. Our study successfully employed Python and TensorFlow to develop a predictive model for drug response in dry eye disease. Through extensive data analysis and feature engineering, we trained a robust model that demonstrated promising accuracy in predicting drug responses. The evaluation metrics, such as precision, recall, and overall accuracy, showcase the model's effectiveness in identifying potential treatments for individuals with dry eye disease.

2. The utilization of TensorFlow facilitates the creation of robust predictive models capable of analyzing complex datasets and extracting meaningful patterns related to drug response. By incorporating various features such as demographic information, clinical symptoms, and biomarkers, these models can effectively predict how patients with dry eye disease will respond to specific medications.

3. The output results, including accuracy metrics, confusion matrices, feature importance, and predicted drug responses, provide valuable insights for healthcare providers in making informed treatment decisions. However, it's essential to interpret these predictions cautiously and consider them in conjunction with clinical expertise and patient preferences.

4. The output results, including accuracy metrics, confusion matrices, feature importance, and predicted drug responses, provide valuable insights for healthcare providers in making informed treatment decisions. However, it's essential to interpret these predictions cautiously and consider them in conjunction with clinical expertise and patient preferences.

6.2 Future Enhancement

1. **Incorporating Multi-Omics Data:** Integrating multi-omics data such as genomics, transcriptomics, proteomics, and metabolomics can provide a more comprehensive understanding of the molecular mechanisms underlying drug response in dry eye disease. Advanced machine learning techniques can be used to analyze and integrate these diverse datasets for improved predictive accuracy.

2. **Exploring Advanced Deep Learning Architectures:** Investigating more complex deep learning architectures, such as attention mechanisms, graph neural networks, or transformers, may offer enhanced predictive capabilities by capturing intricate relationships within patient data. These architectures can effectively model non-linear interactions and dependencies, leading to more accurate drug response predictions.

3. **Implementing Transfer Learning:** Leveraging pre-trained neural network models using transfer learning can accelerate model development and improve performance, especially when dealing with limited datasets in dry eye disease. Fine-tuning pre-trained models on dry eye disease-specific data can capture disease-specific features and enhance prediction accuracy.

4. **Enabling Real-Time Monitoring:** Developing systems for real-time monitoring of patient data and drug response can facilitate early detection of treatment efficacy or adverse reactions. Integrating predictive models into healthcare information systems can enable automated alerts and decision support tools for healthcare providers, enhancing patient care and safety.

5. **Incorporating Longitudinal Data Analysis**: Incorporating longitudinal patient data over time can provide insights into disease progression and treatment response dynamics. Time-series analysis techniques combined with recurrent neural networks or attention mechanisms can effectively model temporal dependencies.

ANNEXURE

Sample Coding

```
import numpy as np
import pandas as pd
import matplotlib.pyplot as plt
import seaborn as sns
import warnings
warnings.filterwarnings('ignore')
from google.colab import files
uploaded = files.upload()
drug_data = pd.read_csv('drug_potability.csv')
drug_data.head()
drug_data.columns
drug_data.shape
drug_data.dtypes
drug_data.info()
drug_data.describe()
drug_data.duplicated().any()
drug_data.isnull().sum()
null_df = drug_data.isnull().sum().reset_index()
null_df.columns = ['columns','null_count']
null_df['miss_value'] = round(null_df['null_count']/len(drug_data),2)*100
null_df
sns.heatmap(drug_data.isnull(),yticklabels =False,cbar=False,cmap='viridis')
plt.show()
drug_data['ph'].plot(kind='hist')
drug_data['Sulfate'].plot(kind='hist')
```

```
plt.show()
drug_data['Trihalomethanes'].plot(kind='hist')
plt.show()
fig = plt.figure()
ax = fig.add_subplot(111)
drug_data['Trihalomethanes'].plot(kind='kde',ax=ax)
plt.show()
drug_data['ph'] = drug_data['ph'].fillna(drug_data['ph'].mean())
drug_data['Trihalomethanes'] =
drug_data['Trihalomethanes'].fillna(drug_data['Trihalomethanes'].mean())
drug_data['Sulfate'] = drug_data['ph'].fillna(drug_data['Sulfate'].mean())
drug_data.isnull().sum()
corr_matrix = drug_data.corr()
corr_matrix
plt.figure(figsize=(18,16))
sns.heatmap(corr_matrix,annot= True,cmap='coolwarm')
plt.show()
corr_matrix1 = corr_matrix.abs()
upper_tri =
corr_matrix1.where(np.triu(np.ones(corr_matrix1.shape),k=1).astype(np.bool
_))
upper_tri
data_hist_plot = drug_data.hist(figsize = (20,20),color ="#5F9EA0" )
for col in drug_data.columns:
  sns.histplot(data =drug_data, x=col, kde=True,hue='Potability')
  plt.show()
drug_data.groupby('Potability').mean().T
drug_data['Potability'].value_counts()
x = drug_data.drop('Potability',axis = 1)
y = drug_data['Potabili
```

```
y.head()
from sklearn.preprocessing import StandardScaler
std_scaler = StandardScaler()
x_scaled = std_scaler.fit_transform(x)
x_scaled
from sklearn.model_selection import train_test_split
x_train,x_test,y_train,y_test =
train_test_split(x_scaled,y,test_size=0.2,random_state=42,stratify=y)
x_train.shape,x_test.shape
from sklearn.linear_model import LogisticRegression
from sklearn.ensemble import RandomForestClassifier
from sklearn.tree import DecisionTreeClassifier
from sklearn.ensemble import ExtraTreesClassifier
from sklearn.ensemble import AdaBoostClassifier
LR=LogisticRegression()
DT=DecisionTreeClassifier()
RF=RandomForestClassifer()
ETC=ExtraTreeesClassifier()
SVM=SVC()
KNN=KNeighborClassifier()
GBC=GradientBoostingClassifier()
ABC=AdaBoostClassifier()
NB=GaussianNB()
from sklearn.model_selection import cross_val_score
models = [LR , DT , ETC , SVM , KNN , GBC , ABC , NB]
features = X_scaled
labels = y
CV = 5
accu_list = []
ModelName = []
```

```
for model in models:
    model_name = model.__class__.__name__
    accuracies = cross_val_score(model, features, labels, scoring = 'accuracy', cv = CV)
    accu_list.append(accuracies.mean()*100)
    ModelName.append(model_name)
    model_acc_df = pd.DataFrame({"Model" : ModelName, "Cross_val_Accuracy" : accu_list})
    model_acc_df
from sklearn.metrics import classification_report
SVM.fit(x_train, y_train)
ETC.fit(x_train, y_train)
RF.fit(x_train, y_train)
y_pred_rf = RF.predict(x-test)
y_pred_svm = SVM.predict(x-test)
y_pred_etc = ETC.predict(x-test)
print(classification_report(y_test, y_pred_rf))
print(classification_report(y_test, y_pred_svm))
print(classification_report(y_test, y_pred_etc))
from sklearn.metrics import roc_curve, auc
y_scores= ETC.predict_proba(x_test)[:, 1]
fpr, tpr, thresholds = roc_curve(y_test, y_scores)
ros_auc = auc(fpr, tpr)

plt.figure(figsize=(7,5))
plt.plot(fpr, tpr, color= 'blue', lw=2, label=f'ROC curve (arrea = {roc_auc})')
plt.plot([0,1],[0, 1], color= 'red', lw=2, linestyle='--')
plt.xlim([0.0, 1.0])
plt.xlim([0.0, 1.05])
ply.xlabel('False Positive Rate')
```

```
ply.ylabel('True Positive Rate')
plt.title('ROC')
plt.legend(loc="lower right")
plt.show()

from sklearn.model_selection import GridSearchCV,RandomizedSearchCV
from sklearn.model_selection import StratifiedKFold
params-Rf={"min_samples_split":[2,6],
        "min_samples_leaf": [1,4],
        "n_estimators" :[100,200,300],
        "criterion"["gini",entropy]
cv_method= StratifiedKFold(n_splits=3)
GridSearchCV_RF = GridSearchCV(estimator=RandomForestClassifier(),
                        param_grid=params_RF,
                       cv=cv_method,
                        verbose=1,
                        n_jobs=2,
                        scoring="accuracy",
                        return_train_score=True)}
GridSearchCV_RF.fit(x_train,y_train)
best_params_RF = GridSearchCV_RF,best_params_
print("Best Hyperparameters for Random Forest are= ",best_params_RF)


scaler = StandardScaler()
X_drug_train = scaler.fit_transform(X_drug_train)
X_drug_test = scaler.transform(X_drug_test)


model = keras.Sequential([
```

```
keras.layers.Dense(64,activation='relu',
input_shape=(X_drug_train.shape[1],), name='input_drug'),
keras.layers.Dense(64, activation='relu', name='input_target'),
keras.layers.Dense(1, name='output')  # Output layer, no activation for regression
])

model.compile(optimizer='adam', loss='mean_squared_error')

X_target_train_flat = X_target_train.reshape(X_target_train.shape[0], -1)

X_target_train_flat = [item for sublist in X_target_train for item in sublist]

flat_data = list(chain(*data))

numpy_array_fixed = np.array(flat_data)

X_drug_train_tensor = tf.constant(X_drug_train, dtype=tf.float32)
X_target_train_flat_tensor = tf.constant(X_target_train_flat, dtype=tf.float32)
model.compile(optimizer='adam', loss='mean_squared_error', run_eagerly=True)
tf.config.run_functions_eagerly(True)

tf.config.run_functions_eagerly(False)

X_target_train_flat_array = np.array(X_target_train_flat)

model.summary()

model.fit({'input_drug_input': X_drug_train, 'input_target':
```

```
X_target_train_flat_array}, y_train, epochs=10, batch_size=32, validation_split=0.2)

X_drug_test = np.array(X_drug_test)
X_target_test = np.array(X_target_test)

y_test_np = np.array(y_test)

y_test_np = y_test_np.astype('float32')

y_test_np_flat = y_test_np.ravel()

y_test_tensor = tf.constant(y_test_np_flat, dtype=tf.float32)

y_test_np = np.ravel(y_test_np)

X_drug_test = np.array(X_drug_test, dtype='float32')
X_drug_test_flat = np.ravel(X_drug_test)

X_drug_test_tensor = tf.constant(X_drug_test, dtype=tf.float32)

X_target_test_flat = [item for sublist in X_target_test for item in sublist]

X_target_test_tensor = tf.constant(X_target_test_flat, dtype=tf.float32)

y_test_tensor = tf.constant(y_test, dtype=tf.float32)

input_data = {
    'input_drug_input': X_drug_test_tensor,  # Replace 'input_drug_input' with the correct input name for the drug features
```

```
    'input_target_input': X_target_test_tensor  # Replace 'input_target_input' with the correct input name for the target features
}

unknown_drug_features = np.array([[0.5, 0.3, 0.8, 0.2, 0.6]])  # Replace with your desired features
unknown_target_features = np.array([[0.7, 0.4, 0.9, 0.1, 0.5]])

unknown_drug_features = scaler.transform(unknown_drug_features)

unknown_combined_features = np.concatenate([unknown_drug_features[:, :5], unknown_target_features[:, :5]], axis=1)

unknown_combined_features_standardized = np.concatenate([unknown_drug_features[:, :5], unknown_target_features[:, :5]], axis=1)

unknown_drug_features_standardized = scaler.transform(unknown_drug_features)

model = keras.Sequential([
keras.layers.Dense(64, activation='relu', input_shape=(10,)),
keras.layers.Dense(64, activation='relu'),
keras.layers.Dense(1)
])

prediction = model.predict(unknown_combined_features_standardized)[0][0]
print(f'Predicted Interaction Score for Unknown Drug: {prediction}
```

REFERENCES

[1] Aben N, Vis DJ, Michaut M, et al. TANDEM: a two-stage approach to maximize interpretability of drug response models based on multiple molecular data types. Bioinformatics 2016;32:i413–20.

[2] Adam G, Rampásek L, Safikhani Z, ˇ et al. Machine learning approaches to drug response prediction: challenges and recent progress. NPJ PrecisiOn col 2020;4:19.

[3] Ahmed Al Marouf ,Md Mozaharul Mottalib ,Reda Alhajj ,Jon Rokne 2020

[4] Ahmed KT, Park S, Jiang Q, et al. Network-based drug sensitivity prediction. BMC Med Genomics 2020;13:193.

[5] Ali M, Aittokallio T. Machine learning and feature selection for drug response prediction in precision oncology applications. Biophys Rev 2019;11:31–9.

[6] Andrea M. Storåsa,c, , Inga Strümkea , Michael A. Rieglera , Jakob Grauslundb , Hugo L. Hammera,c, Anis Yazidic , Pål Halvorsena,c, Kjell G. Gundersenf , Tor P. Utheimc,d,e, Catherine Jacksonf,2021

[7] Baptista D, Ferreira PG, Rocha M. Deep learning for drug response prediction in cancer. Brief Bioinform 2021;22:360–79.

[8] Bishop CM. Pattern Recognition and Machine Learning, 2nd edn. New York, NY: Springer Science, 2006.

[9] Bouhaddou M, DiStefano MS, Riesel EA, et al. Drug response consistency in CCLE and CGP. Nature 2016;540:E9–10.

[10] Chen J, Zhang L. A survey and systematic assessment of computational methods for drug response prediction. Brief Bioinform 2021;22:232–46

[11] Coste Geeleher P, Cox NJ, Huang RS. Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines. Genome Biol 2014;15:R47.

[12] De Niz C, Rahman R, Zhao X, et al. Algorithms for drug sensitivity prediction. Algorithms 2016;9:77.

[13] Emdadi A, Eslahchi C. Auto-HMM-LMF: feature selection based method for prediction of drug response via autoencoder and hidden Markov model. BMC Bioinformatics 2021;22:33.

[14] Huang E, Bhope A, Lim J, et al. Tissue-guided LASSO for prediction of clinical drug response using preclinical samples. PLoSComputBiol 2020;16:e1007607.

[15] llo JC, Heiser LM, Georgii E, et al. A community effort to assess and improve drug sensitivity prediction algorithms. Nat Biotechnol 2014;32:1202–12

[16] Johann de Jong, Ioana Cucu tache, Matthew Page, Sami Elmoufti, Cynthia Dilley, HolgerFröhlich, Martin Armstrong. 2023-2782-22

[17] Kanehisa M, Furumichi M, Tanabe M, et al. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res 2017;45:D353–61

[18] Koras K, Juraeva D, Kreis J, et al. Feature selection strategies for drug sensitivity prediction. Sci Rep 2020;10:9377

[19] Libbrecht MW, Noble WS. Machine learning applications in genetics and genomics. Nat Rev Genet 2015;16:321–32.

[20] Matlock K, De Niz C, Rahman R, et al. Investigation of model stacking for drug sensitivity prediction. BMC Bioinformatics 2018;19:71.

[21] Micaglio E, Locati ET, Monasky MM, et al. Role of pharmacogenetics in adverse drug reactions: an update towards personalized medicine. Front Pharmacol 2021;12:651720.

[22] Mpindi JP, Yadav B, Östling P, et al. Consistency in drug response profiling. Nature 2016;540:E5–6.

[23] Pristner M, Warth B. Drug-exposome interactions: the next frontier in precision medicine. Trends PharmacolSci 2020;41:994–1005

[24] Pryor R, Martinez-Martinez D, Quintaneiro L, et al. The role of the microbiome in drug response. Annu Rev PharmacolToxicol 2020;60:417–35.

[25] Savage N. The complex relationship between drugs and the microbiome. Nature 2020;577:S10–1.

[26] Sharifi-Noghabi H, Zolotareva O, Collins CC, et al. MOLI: multi-omics late integration with deep neural networks for drug response prediction. Bioinformatics 2019;35:i501–9.

[27] Sharma A, Rani R. Drug sensitivity prediction framework using ensemble and multi-task learning. Int J Mach Learn Cybern 2019;11:1231–40.

[28] Stanfield Z, Coskun M, Koyutürk M. Drug response prediction as a link prediction problem. Sci Rep 2017;7:40321.

[29] Tentler JJ, Tan AC, Weekes CD, et al. Patient-derived tumor xenografts as models for oncology drug development. Nat Rev ClinOncol 2012;9:338–50.